Tioxolone niosomes exert antileishmanial effects on *Leishmania tropica* by promoting promastigote apoptosis and immunomodulation

Maryam Hakimi Parizi¹, Iraj Sharifi¹✉, Saeedeh Farajzadeh², Abbas Pardakhty³, Mohammad Hossein Daie Parizi³, Hamid Sharifi⁵, Ali Reza Keyhani¹, Mahshid Mostafavi¹, Mehdi Bamorovat⁶, Ahmad Khozravi¹, Daryoush Ghaffari¹

¹Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran
²Department of Pediatric dermatology, Kerman University of Medical Sciences, Kerman, Iran
³Pharmaceutics Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran
⁴Department of Pediatrics, Kerman University of Medical Sciences, Kerman, Iran
⁵HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran
⁶Research Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran

ARTICLE INFO

**ABSTRACT**

**Objective:** To explore the antileishmanial effect of tioxolone and its niosomal form against *Leishmania tropica*.

**Methods:** Tioxolone niosomes were prepared by the hydration method and were evaluated for morphology, size, release study, and encapsulation efficiency. The cytotoxicity of tioxolone and its niosomal form was measured by MTT assay, leishmanicidal activity against promastigote and amastigote by MTT assay, apoptosis by flow cytometry, *IL-12*, *IL-10* and metacaspase gene expression levels by q-PCR.

**Results:** Span/Tween 40 and Span/Tween 60 niosomes had good physical stability as depicted in their size distribution curves and high encapsulation efficiency (>99%). The release profile of the entrapped compounds showed Fickian’s model of tioxolone delivery based on diffusion through lipid bilayers. With the IC₅₀ value for amastigote as (24.5±2.1) μg/mL and selectivity index as 10.5, the Span/Tween 60 niosome (NT₂) had a superior effect to other drugs. The CC₅₀ value and IC₅₀ of promastigote value for NT₂ were (257.5±24.5) μg/mL and (164.8±20.6) μg/mL, respectively. The flow cytometric analysis showed that tioxolone and niosomal forms induced apoptosis of *Leishmania tropica* promastigotes in a dose-dependent manner. NT₂ increased the expression level of *IL-12* and metacaspase genes and decreased the expression level of the *IL-10* gene.

**Conclusions:** Niosomes of tioxolone play an immunomodulatory role in increasing Th1 cytokine profile and inhibiting the Th2 cytokine profile. It could be used for treatment of anthroponotic cutaneous leishmaniasis.

1. Introduction

Cutaneous leishmaniasis (CL) is a vector-borne, neglected tropical disease caused by over 20 obligatory intracellular protozoa of the *Leishmania* species. It is transmitted by the bite of phlebotomine sandflies[1]. The clinical manifestations of the disease vary considerably in CL and are quite complex, from self-limiting...
to even death if left untreated[1]. The most affected countries are Afghanistan, Algeria, Brazil, Iraq, Iran, and Syria. In the world, 1-1.5 million new cases of the disease are reported annually; almost 431 million people are at risk of CL in CL high-burden countries[2].

In the Old World, including Iran, two clinical and epidemiological forms of CL are present. Zoonotic CL caused by *Leishmania (L)* major infects small gerbils as the main reservoir host and *Phlebotomus papatasi* is the principal vector. While anthropotonic CL due to *L. tropica* infects humans as the major reservoir and *Phlebotomus sergenti* is the main vector. Anthropotonic cutaneous leishmaniasis (ACL) is transmitted by the bite of female phlebotomine sand flies through an urban life cycle anthropologically (man-to-man transmission)[2]. According to recent reports, the total number of CL cases in Iran is 21 148 annually and the population at risk of CL is 58% (18/31 provinces)[2]. But it is believed that the actual number of cases is 2-5 times higher than reported[3].

In the absence of a practical and efficacious vaccine, the first-line therapeutic options for CL usually rely on the injection of pentavalent antimonials such as Glucantime® [meglumine antimoniate (MA)][3]. However, these compounds have many side effects, variable efficacy, high cost, and drug-resistance. Moreover, treatment has some complications, such as painful injection, especially in children when the lesion is located on the face. Additionally, injection is not recommended when the parasite has progressed to the lymph nodes and cartilages. Systemic therapeutics with pentavalent antimonials or the second-line compound including pentamidine, amphotericin B, or oral miltefosine are valuable with pentavalent antimonials or the second-line compound including pentamidine, amphotericin B, or oral miltefosine are valuable alternatives, but their uses are also limited due to their unwanted adverse effects and cost[4].

An alternative treatment for CL skin problems involves topical treatments. Advantages of using this therapy are superior compliance of patients, reduction of costs, minimized drug resistance, and avoidance of systemic toxicity. Topical treatment is currently limited to the least severe forms of CL without risk of dissemination. Topical treatments such as cryotherapy, thermotherapy, photodynamic therapy, imiquimod cream, ketoconazole and allopurinol have been reported, but they have only been effective in combination with other therapies[5].

Among several approaches, the use of vesicular formulations could increase penetration and sustained-release effect of drugs across the skin[6]. These formulations improve the drug release profile, reduce undesirable side effects, decrease effective amount of drug and increase their survival time in biological systems to enhance drug efficacy. The unique construction of these vesicles is niosome produced from nonionic surfactants in the aqueous phase[6]. This vesicle is found to be efficient in topical drug delivery as it can enhance residence time of drugs in the skin, and promote the drug to penetrate into the skin in stratum corneum and to deliver in the deeper layer of the epidermis. Also, niosome enhances the penetration of different substances in cells such as Langerhans cells, thus, it can be effective to treat intracellular infection such as *Leishmania* infection[6-8]. Aflatoonian et al. showed that niosomal topical dapsone gel could be used as an efficient alternative treatment to cryotherapy in CL due to its fewer side effects[8]. In addition, Farajzadeh et al. reported that a combination of niosomal zinc sulphate with intralesional glucantime had equal efficacy versus a combination of cryotherapy plus intrallesional glucantime in the treatment of acute CL. So, it can be used in cases that are resistant to first-line treatments[9]. Asadi et al. showed that the topical niosomal formulation of paromomycin with better penetration and efficacy could be used as a new topical drug delivery system for treatment of CL[10]. Also, in another study, it was mentioned that ketoconazole niosomal gel enhanced its penetration across the stratum corneum[11].

Daie Parizi et al. reported the therapeutic effect of topical application of tincture containing a mixture of two drugs, tioxolone and benzoxonium chloride. This formulation was named Thio-Ben. They evaluated the efficacy of Thio-Ben and found that the effect of this drug was not significantly different from that of MA. Also, due to the topical application of Thio-Ben, its side effects were much lower than MA[12].

Benzoxathiol derivatives, especially 6-hydroxy-1, 3-benzoxathiol-2-one (called also tioxolone) have been used for local treatment of acne and psoriasis vulgaris. They are also known as anti-fungal and anti-bacterial. The reports showed that benzoxathiol derivatives had anti-inflammatory and anti-tumorigenic effects through inhibition of NF-κB and STAT3 activation[13,14].

Since the niosomal formulation of this drug may potentially be more effective, this study was designed to evaluate the possible effect of the niosomal form of tioxolone on *L. tropica* in *in vitro* model.

### 2. Materials and methods

#### 2.1. Chemicals and reagents

MA (Glucantime®) 1.5 g/5 mL solution for injection as a positive control drug was purchased from Sanofi-Aventis, France. Penicillin-streptomycin (10 000 U/mL) was obtained from Thermo Fisher Scientific, USA and was frozen at -20 °C until testing. 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) powder (Thiazolyl blue), product No. M 5655 was purchased from Sigma-Aldrich®, USA. Fetal bovine serum was purchased from Gibco, USA. DMEM medium with sodium pyruvate and RPMI-1640 medium with stable glutamine were purchased from Biosera, France. Sorbitan esters (Span) and their pegylated derivatives (Tween), cholesterol, and 6-hydroxy-1, 3-benzoxathiol-2-one (tioxolone) were purchased from Sigma-Aldrich®, USA. Ethanol, dimethyl sulphoxide, and chloroform were purchased from Merck (Germany). Phycoerythrin (PE) Annexin V Apoptosis Detection Kit was purchased from BD Pharmingen™, USA. Phosphate buffered saline was purchased from Cassion Lab, USA.

#### 2.2. Niosome preparation

Tioxolone niosomes were prepared by the hydration method described by Pardakhity et al[15]. Briefly, the appropriate amounts of
non-ionic surfactants (Span/Tween 20, 40, 60, and 80), cholesterol, and tioxolone (5000 μg/mL) were dissolved in chloroform in 100 mL round-bottom flasks. The solvent was evaporated using a rotary evaporator (Buchi, Switzerland) at 180 rpm and 70 °C for 15 min. The thin layers of lipids formed on the internal wall of the flask were hydrated by adding 5 mL of deionized water at 70 °C for 30 min. These formulations were stored at room temperature for further study.

2.3. Characterization of niosomes

2.3.1. Morphological evaluation of lipid vesicles

The type and shape of vesicles and probable niosomal constituents, crystallization/separation or aggregation were observed using optical microscopy (Zeiss, Germany) with emergent micrographs captured.

2.3.2. Niosomes size analysis

Size of non-ionic surfactant vesicles was assessed by measuring their dynamic light scattering with Master Sizer 2000 E (Malvern, UK). Results were presented as average volume diameters of vesicles. All measurements were performed in triplicate. Also, physical stability of niosomes was determined by size variations over 3 days, 1, 3, and 6 months after production[16].

2.3.3. Release study

Release profiles of entrapped materials were determined by dialysis method[16] in selected formulations, after passing 1 mL of the formulations from the dialysis bag (cellulose acetate membrane, Sigma-Aldrich, Germany) at 37 °C at certain time intervals (0, 15, 30, 60, 90, 120, 150, 180, 210 and 240 min). One mL of the receiver containing 96% ethanol-deionized water (50/50 volume %) was removed and replaced with the same amount of fresh receptor phase. The un-entrapped drug was separated by dialysis method, and then finally analyzed by the spectrophotometry method to calculate the encapsulation efficiency
drugged as per the following equation:

\[ \text{% Encapsulation efficiency} = \frac{\text{Total drug-free non entrapped drug}}{\text{Total drug}} \times 100 \]

2.3.4 Encapsulation efficiency

The un-entrapped drug was separated by dialysis method, and then niosome was digested by isopropanol. The resultant solution was finally analyzed by the spectrophotometry method to calculate the entrapped drug[16] as per the following equation:

\[ \text{% Encapsulation efficiency} = \frac{\text{Total drug-free non entrapped drug}}{\text{Total drug}} \times 100 \]

2.4. Parasite strain and culture

The standard strain of L. tropica (MHOM/IR/2002/Mash2) was prepared from the Leishmaniasis Research Center (Kerman, Iran). The parasite was cultured in RPMI-1640, 1 μL penicillin-streptomycin (10 000 U/mL) and 15% heat-inactivated fetal bovine serum, and then incubated at (25±1) °C.

2.5. Cytotoxicity assay

In this study, the cytotoxic effects of tioxolone and its niosomal forms against murine macrophage cells (J774 A.1 ATCC®TIB-67® purchased from the Pasteur Institute of Iran) were determined. Macrophages (5 × 10^4 cells/mL) with various concentrations of drugs (0-500 μg/mL) were cultivated in 96-well tissue culture plates at 37 °C and 5% CO₂ for 48 h. MTT assays were used to investigate the cytotoxicity of the formulations of tioxolone in comparison with the standard drug. MTT at 5 mg/mL was dissolved in RPMI-1640 without phenol red in our experiment. The solution was filtered through a 0.2 μm filter and stored at 2–8 °C for frequent use, or frozen for extended periods. MTT stock solution (5 mg/mL) was added routinely to each culture to equal one-tenth of the original culture volume and then incubated for 3 to 4 h. After that, the medium was removed and acidic isopropanol (0.04–0.10 mol/L HCL in absolute isopropanol) was added to stop the reactions. When working with cell suspension, the dye was added directly and dissolution was accomplished by titration. Absorbance of converted dye was measured by an ELISA reader (BioTek-ELX800 Winooski, Vermont, USA) at a wavelength of 490 nm. The percentage of living cells for each repetition (cell viability) was obtained by the following formula:

\[ \frac{(A-B)}{(C-B)} \times 100 \]

Where A is average optical density (OD) of treat (media+macrophage cells+drug), B is average OD of negative control (media) and C is average OD of positive control (media+macrophage cells). From the percentage of cell viability, dose-response curves and 50% cytotoxicity concentration values (CC_{50}) were calculated using probit analysis in SPSS software.

A transformed version of proportions was used instead of regressing the actual proportions in probit regression. In probit transformation, each proportion was replaced with the value of the standard normal curve below which is the observed proportion of the area. The regression equation derived could be used to estimate CC_{50}, where the value of probit is set to zero. The output of the model in the graphs and tables is used to calculate CC_{50}.

2.6. Anti-leishmanial activity against promastigote

Leishmanial activity of tioxolone and its niosomal forms at the promastigote stage of L. tropica was evaluated by MTT assay. Initially, promastigotes in logarithmic growth phase (10^7 cells/mL) were added into a 96-well tissue culture plate. Then, varying concentrations of tioxolone, its niosomal forms, or MA alone (positive control) were added to each well and incubated at (25±1) °C for 48 h (concentrations based on cytotoxicity results). After incubation, 10 μL of MTT solution (5 mg/mL) was added into each well and they were allowed to incubate at 25 °C for 4 h. Promastigotes without drug and complete medium with no promastigote and drug were used as untreated control and blank, respectively. All experiments were repeated in triplicate. Finally, absorbance was measured at 490 nm. Dose-response curves and 50% inhibitory concentration values (IC_{50}) were calculated using probit analysis in SPSS software as mentioned for calculation of CC_{50} in the previous section.
2.7. Anti-leishmanial activity against intramacrophage amastigote

A total of 100 μL of macrophage culture (1 × 10^5 per mL) was added to each slide (75 mm × 25 mm) and placed in a sterile Petri dish, which was incubated for 4 h at 37 °C and 5% CO₂. Host cells were then infected at a 1:10 ratio (macrophage: promastigote) in stationary phase parasites (L. tropica) and further incubated for 24 h at 37 °C, 5% CO₂, and 85% relative humidity. The next day, drug concentrations similar to promastigote assay were added in triplicates. After confirming macrophage infection levels above 80% (with light microscopy), 100 μL of drugs diluted in DMEM medium were added to the infected macrophages. In addition, the macrophages containing amastigotes without drug and complete medium without parasite and drug were considered untreated control and blank, respectively. After incubation for 48 h at 37 °C, the medium was removed and the slides fixed with 100% methanol for 2 min. They were then stained with Wright Giemsa for 15 min. The number of amastigotes in 100 macrophages was evaluated for each treatment by direct observation under light microscope.

Percentage inhibition was calculated by using the following formula:

\[ PI = \frac{(PC - PT)}{PC} \times 100 \]

Where PI is the percentage of inhibition, PC the number of amastigotes/100 infected macrophages in the control slide and PT the number of amastigotes/100 infected macrophages in the drug-treated slide. The IC₅₀ was obtained using probit test in SPSS software as mentioned for calculation of CC₅₀ in the 2.5 section. In addition, the selectivity index (SI) was calculated by the following formula: SI=50% cytotoxicity concentration on macrophages/50% inhibition concentration on amastigotes.

2.8. Apoptotic cell determination

The apoptosis kit used for flow cytometry was the two-channel PE Annexin V and 7-amino actinomycin (7-AAD) with PE Annexin V Apoptosis Detection Kit (BD PharmingenTM). 1 × 10^5 L. tropica promastigotes were seeded into the microtube and the highest concentrations, as well as concentrations of 50 μg/mL and 12.5 μg/mL of each drug were added following incubation at 25 °C for 48 h. Promastigotes were washed twice with cold PBS and were suspended in 1× binding buffer. Then, 100 μL of the solution (1 × 10^5 parasites) was transferred to a 5 mL culture tube and 5 μL of PE Annexin V and 5 μL 7-AAD were added. Promastigotes were incubated for at least 15 min at room temperature (25 °C) in the dark. Finally, 400 μL of 1× binding buffer was added to each tube, which was then analyzed by flow cytometry (BD FACSCalibur™, USA) within 1 h.

PE Annexin V staining enters cells losing their entire membrane, which accompanies either apoptosis or necrosis processes. Cells that are PE Annexin V and 7-AAD negative are considered viable; cells that are PE Annexin V positive and 7-AAD negative are in early apoptosis; and cells that are both PE Annexin V and 7-AAD positive are in late apoptosis or already dead.

2.9. mRNA transcripts

Levels of relative expression of interleukin-12 (IL-12) and interleukin-10 (IL-10) in murine macrophage cells (J774 A.1) and metacaspase genes in promastigotes were detected by quantitative real-time PCR (q-PCR) assay. In brief, RNA was extracted from various concentration (200 μg/mL, 100 μg/mL, 50 μg/mL and 12.5 μg/mL) of superior drug
(NT₃), MA and untreated control group using the RNeasy mini kit (Qiagen, Chatsworth, CA, USA) based on the producer’s protocol. The cDNA was synthesized by a first-strand cDNA synthesis kit (Takara Bio, Inc., Shiga, Japan).

The qPCR reaction was carried out in duplicate with the Rotorgene Cycler System (Rotorgene 3000 Cycler System, Corbett Research, Sydney, Australia) and a SYBR Green experiment (SYBR Premix Ex Taq™, Takara Bio, Inc., Shiga, Japan).

Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as reference genes. The gene expressions of IL-12 and IL-10 in murine macrophage cells (J774 A.1) and metacaspase in promastigote were detected by q-PCR assay[17]. The primers are as shown in Table 1. At the first test, the PCR was performed at 95 °C for 5 min and then the cDNA was amplified by 40 three-step cycles (10 s at 95 °C for denaturation of DNA, 15 s at 58 °C for primer annealing, and 20 s at 72 °C for extension). The final temperature was 65 °C for 1 min. The ΔCT was measured by means of the following formula:

\[ \Delta CT = CT_{\text{target}} - CT_{\text{reference}} \]

Gene expression level was specified by the 2^(-ΔCT) method. Moreover, the fold increase (FI) was measured through the comparative threshold method (2^(-ΔΔCT)).

2.10. Statistical analysis

Data were entered into a computer using the SPSS software version 20 (Chicago, IL, USA). ANOVA and independent t-test were used to analyze the difference among the treatment groups. The 50% inhibitory concentration (IC₅₀) and 50% cytotoxicity concentration (CC₅₀) values were analyzed by probit with SPSS software. *P<0.05 was considered a significant level.

3. Results

3.1. Niosome characterization

Different formulations of tioxolone were prepared. Based on the morphology of the niosomes (round multilamellar vesicles) and the particle size distribution, the best formulations were chosen as Span/Tween 40 (ST40, 6:4 molar ratio) and Span/Tween 60 (ST60, 6:4 molar ratio) (Figure 1). Niosomes were formed in the presence of different amounts of cholesterol as spherical bilayer vesicles. Both formulations demonstrated lognormal particle size distribution curves (Figure 1A & C). The selected formulations had good physical stability as depicted in their size distribution curves during 3 days, 1, 3, and 6 months at room temperature. Tioxolone in ST40 (NT₁) and ST60 (NT₂) niosomes displayed high encapsulation efficiency (more than 99%).

The release profile of entrapped compounds in the selected formulations demonstrated Fickian’s model of tioxolone delivery based on diffusion through lipid bilayers (Figure 2).

3.2. Optimize concentration without toxicity

Based on the CC₅₀, dosages lower than the toxic doses (CC₅₀) were selected for anti-leishmanial assays. The CC₅₀ values for tioxolone and its niosomal forms (NT₁ and NT₂) were (169.4±15.3) μg/mL, (134.4±10.5) μg/mL, and (257.5±24.5) μg/mL against J774, respectively.

369

Table 1. Sequences of forward and reverse primers and reference genes for quantitative real time PCR.

| Template          | Forward sequence (5'→3') | Reverse sequence (5'→3') | Product size (bp) |
|-------------------|--------------------------|--------------------------|-------------------|
| IL-12             | CTTGAGCACTCCCCATTCCTTA   | GCAGACATCCCCGCTTGT      | 160               |
| IL-10             | CTATCTAGTGATGAGATCA      | GCACCTCTAGACGATGC       | 101               |
| Meta caspase      | CAGACAATTCCTGGGGGATA     | AAGTTTGAAGAAAAAGGAACATTTG| 140               |
| 40S               | GCTGGAAGTGCTGCTGCTG      | TGCAGGTGTGCTGAGGCTT     | 166               |
| GAPDH             | AGCTTCGGACATATTCCTCTG    | CGTTCACTCCCATGCAACA     | 89                |

Table 2. Effect of tioxolone, niosomal forms of tioxolone and meglumine antimoniate on intramacrophage amastigote of Leishmania tropica.

| Concentration(μg/mL) | No. of amastigote/100 infected macrophages | Meglumine antimoniate |
|----------------------|-------------------------------------------|-----------------------|
|                      | Tioxolone | NT₁ | NT₂ |          |
| 0.0 (Control)        | 60.71±1.46 | 60.71±1.46 | 60.71±1.46 | 60.71±1.46 |
| 12.5                 | 46.86±1.76 | 34.43±1.07  | 41.43±1.46  | 54.20±1.06  |
| 25.0                 | 32.90±0.87  | 29.56±1.90  | 26.46±1.38  | 41.86±1.02  |
| 50.0                 | 26.70±0.96  | 25.60±1.30  | 19.50±1.87  | 34.46±2.05  |
| 100.0                | 24.90±0.66  | 21.33±1.13  | 18.10±0.55  | 31.46±1.91  |
| 150.0                | 22.50±1.17  | -             | 17.06±0.92  | 28.16±2.01  |
| 200.0                | -             | -             | 17.06±0.75  | 22.96±2.62  |

Data represent the mean value ± standard deviation, *P<0.05 compared with control.
3.3. Anti-leishmanial activity against promastigote

Various concentrations of tioxolone, niosomal forms of tioxolone (NT1 and NT2) and MA showed percentage of inhibition of L. tropica promastigotes in a dose-dependent manner, as presented in Figure 3A. The IC50 values of tioxolone, NT1 and NT2 were (56.1±5.2) μg/mL, (94.3±13.3) μg/mL, and (164.8±20.6) μg/mL against promastigotes of L. tropica, respectively. However, the IC50 value of MA was much higher ([536.5±40.0] μg/mL) as the positive control drug. The IC50 values of tioxolone, NT1, and NT2 were significantly lower than the MA (P<0.001). These results also revealed that tioxolone had a more pronounced leishmanicidal effect on the promastigote of L. tropica in comparison with NT1 and NT2, although the difference was not significant with NT1.

3.4. Anti-leishmanial activity against intramacrophage amastigote

Anti-leishmanial activity of drugs in the macrophage model was evaluated by counting the number of amastigotes in 100 macrophages in triplicate (Table 2). Various concentrations of tioxolone, NT1, NT2, and MA were all able to inhibit the multiplication rate of amastigotes significantly in each macrophage as compared with the untreated control (P<0.05). The IC50 values of tioxolone, NT1, NT2 and MA were (49.8±3.4) μg/mL, (23.3±2.8) μg/mL, (24.5±2.1) μg/mL, (101.8±4.2) μg/mL against amastigotes of L. tropica, respectively. In addition, the amastigote inhibition rate of NT1 was higher than the other drugs and the standard drug (Figure 3B). Besides, NT2 also displayed the highest SI (10.5).

3.5. Apoptotic cell determination

The levels of apoptotic cells, necrotic cells, and viable cells in three different concentrations of each drug were determined and compared with the untreated control and positive control (MA). The highest (58.9%) rate of apoptosis in promastigotes occurred at 150 μg/mL concentration in tioxolone, while it was 0.34% in the untreated control (Figure 4A). Also, NT1 (200 μg/mL), NT2 (100 μg/mL), and MA (100 μg/mL) showed the high apoptosis (37.35%, 29.11%, and 27.4%, respectively). The levels of necrosis in tioxolone (150 μg/mL), NT2 (200 μg/mL), NT1 (100 μg/mL), and MA (100 μg/mL) were 11.2%, 6.38%, 6.13%, and 8.93%, respectively (Figure 4).

3.6. qPCR results

The genes expression of IL–12 and metacaspase were increased, while expressions of IL–10 were decreased in NT2 and MA group comparing with untreated group (Figure 5). IL–12 and metacaspase expression showed significant difference between MA and NT2 in all the concentrations (P<0.05), but the significant difference in IL–10 expression was observed only at 12.5 μg/mL concentration (P<0.05) (Figure 5).

4. Discussion

Pentavalent antimonials have been the standard, first-line drugs against leishmaniasis for several decades. The emergence of resistance to antimonials, especially in anthroponotic CL foci, has required newer treatment modalities like combination therapies and vesicular forms of drugs[18,19]. Also, the use of topical drugs instead of oral, intravenous and/or intramuscular treatments can reduce systemic side effects[20-22]. A problem with topical use is their low penetration rate into the stratum corneum barrier. Recently, to overcome this problem as well as to facilitate the gradual release of the drug, vesicle structures such as niosomes have been used[6,7].

The previous study has shown that tioxolone and benzoxonium chloride demonstrate a high index of antileishmanial effect on humans[12]. Tioxolone is a biologically active compound and possesses cytoplastic, antipsoriatic, antibacterial, and antimycotic properties. Therefore, it has been widely used for various skin and scalp disorders for many years[14,23]. Because it contains ester and thioester groups, tioxolone is also applied in the synthesis of heterocycle-phosphor esters with potential antimicrobial activity[24]. Additionally, the study of Tripp’s group showed that tioxolone...
Figure 4. Flow cytometry results showing early and late apoptosis as well as necrotic cells after treatment with A: various concentrations of tioxolone (T), B & C: niosomal forms of tioxolone (NT₁ & NT₂) and D: meglumine antimoniate (MA) for 48 h.

Figure 5. Effect of different concentrations of NT₂ on genes expression of IL-12 (A), IL-10 (B), and metacaspase (C) of *Leishmania tropica*. One-way ANOVA followed by Bonferroni post hoc test. *P<0.05 compared to untreated parasites (control), *P<0.05 compared between MA and NT₂.
is a potential carbonic anhydrase inhibitor and possesses several medical applications, such as treating glaucoma, Alzheimer’s disease, osteoporosis, and managing epilepsy and diuretics[24,25]. Tioxolone inhibits the enzyme carbonic anhydrase, which catalyzes the conversion of carbon dioxide and water to bicarbonate ions and protons[26]. This reversible reaction helps maintain the acid-base balance within blood and tissues. Tioxolone could even inhibit this overexpression of carbonic anhydrase, leading to loss of the advantage over cancer cells[26]. In a study on some viruses, IC₅₀ of tioxolone achieved 16.24 μg/mL[27].

Determination of niosome size is necessary because this factor is very effective on the biodistribution and plasma pharmacokinetics of niosomes. During this study, NT₂ formulations had more sustainability from three days to sixth months. Due to long and saturated hydrocarbon chain of Span 40 (C16) and Span 60 (C18), gel state lipid bilayers will be formed[28] in comparison to short hydrocarbon chain of Span 20 (C12) or unsaturated chain of Span 80 (C9) which both resulted in liquid state of lipid bilayers[29]. Liquid state lipid vesicles usually have less stability and encapsulation efficiencies[30]. This effect was previously reported for niosomes containing autoclaved L. major prepared by Span60[15]. On the other hand, incorporation of polyoxylated derivatives of sorbitan esters, Tweens, will increase the steric stability of prepared niosomes[31].

Considering that the hydration method of the fatty layer was used in manufacture of niosomes, the diameters of the niosomes were larger than 5 μm. The level of entrapment efficacy in both formulations was very high and the rate of release in the formulation showed that both of them were slow-release. Vesicular systems including niosomes are novel means to deliver drug in a controlled manner that both of them were slow-release. Vesicular systems including niosomes are novel means to deliver drug in a controlled manner to enhance bioavailability and therapeutic effect over a longer period[32]. Tioxolone in free solution form dialyzed completely and rapidly during the first one hour (data not shown). On the other hand, the release profile of niosomal-entrapped material showed an incomplete release profile, less than 65% after 240 min. Two phases release profiles of encapsulated material which shown in our previous studies[15,30], have not been obtained in present research. This difference may be due to the high volume of the receptor compartment in dialysis method (200 mL) used in this study, in comparison to Franz diffusion cell (usually less than 40 mL).

Cytotoxicity assay showed that NT₂ had less toxicity than tioxolone and NT₁ against 1774 A.1. In addition, the highest level of SI was obtained at NT₂ (10.5). It is generally considered that biological efficacy is not due to in vitro cytotoxicity when SI≥10, therefore, this formulation showed antileishmanial activity with no toxicity as represented by good SI[33]. The IC₅₀ value of tioxolone for promastigote was lower than NT₁ and NT₂; on the other hand, its inhibitory effect was higher as exhibited by flow cytometry analysis. However, according to the IC₅₀ for amastigote and SI, the NT₂ formulation appears to have a better effect than the other drugs. The IC₅₀ values of tioxolone and its niosomal forms on promastigotes were higher than that on the amastigote. Despite being inside the macrophages within the vertebrate hosts including humans, the intrinsic susceptibility of amastigote at clinical stage is attributed to physiological and biochemical differences. As previously indicated by many authors, amastigotes are more susceptible to pentavalent antimonials. It is generally accepted that pentavalent antimonials act as prodrug and undergo biological reduction to trivalent antimony within the intra-macrophage amastigotes, which is much more active antileishmanial form. While promastigotes as non-clinical and extracellular form, are not able to reduce pentavalent antimonials[34].

Programmed cell death in the flagellated protozoan parasite Leishmania has been accepted by most authors. It has been described as apoptosis[35]. In Leishmania promastigotes, cells lack any detectable levels of phosphatidylserine, a phospholipid that is exposed at the surface of metazoan cells in response to apoptotic stimuli, and it is not an apoptosis marker in this parasite[36]. Instead, several other phospholipid classes, such phosphatidic acid, phosphatidylethanolamine, phosphatidylglycerol, and phosphatidylinositol, have been identified as candidate lipids by annexin V staining[37]. Our flow cytometry results showed tioxolone-induced apoptosis in a dose-dependent manner in L. tropica promastigotes.

IL-12 (one of the Th1 cytokines) is an important regulatory cytokine that initiates and regulates cellular immune responses and plays a crucial role in both innate and adaptive immunity of host against predominantly intracellular pathogens[38]. In our study, the level of IL-12 gene expression increased with increasing concentrations (NT₂), which was significantly higher than the positive control (MA). It indicates that NT₂ plays an immunomodulatory role in induction of IL-12 and inhibition of Th2 cytokine gene profiling. This leads to increase in the Th1 cytokine profile, which could make it potentially applicable for treatment of ACL. Experimental studies indicate that IL-10 has potent immunosuppressive activity in leishmaniasis, including suppression of macrophage activation. Moreover, IL-10 production has a strong correlation with disease progression[39]. In our study, by increasing the concentration of the drug, the expression of IL-10 was declined.

Metacaspases are caspase family cysteine peptidases that have been implicated in cell death processes in plants, fungi, and protozoa[40]. The single metacaspase of L. major has a major role in the cell cycle and programming cellular death[40]. The metacaspase of L. donovani has a function in cell death pathways[41]. This study also showed that NT₂ increased metacaspase in promastigotes of L. tropica, and could lead to immune responses towards host-protective Th1 response. Increasing the expression of the metacaspase gene contributes to apoptosis, which was consistent with the flow cytometry result[42].
In ACL, since human is the main reservoir and transmission is anthroponotic, chemotherapy is the most effective means to control the disease[2]. Moreover, due to emerging resistance to antimonials[18], the impending challenges necessitate more effective treatment modality and the development of new types of drugs.

The niosomal formulation improves anti-leishmanial activities of tioxolone and promotes a protective immune response to L. tropica. Further investigations using in vivo and human model are needed.

**Conflict of interest statement**

The authors declare that they have no conflict of interest.

**Foundation project**

The present study was part of a Ph.D. thesis and financially supported by the Iran National Science Foundation under Grant ID 95839151 to Saeedeh Farajzadah.

**References**

[1] Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. *PloS One* 2012; 7(5): e35671.

[2] World Health Organization (WHO). WHO: Weekly epidemiological record *Relevé épidémiologique hebdomadaire*. Geneva: WHO; 2016, p. 421-428.

[3] Shirzadi MR, Gouya MM. National guidelines for cutaneous leishmaniasis surveillance in Iran. Tehran, Iran: MoHaME Zoonoses Control Departemnt; 2010, p. 1-78.

[4] Khatami A, Firooz A, Gorouhi F, Dowlati Y. Treatment of acute Old World cutaneous leishmaniasis: A systematic review of the randomized controlled trials. *J Am Acad Dermatol* 2007; 335: e1-e29.

[5] Moreno E, Schwartz J, Fernández C, Sammartin C, Nguewa P, Irache JM, et al. Nanoparticles as multifunctional devices for the topical treatment of cutaneous leishmaniasis. *Expert Opin Drug Deliv* 2014; 11(4): 579-597.

[6] Choi MJ, Maibach HI. Liposomes and niosomes as topical drug delivery systems. *Skin Pharmacol Physiol* 2005; 18(5): 209-219.

[7] Moosavian Kalat SA, Khamesipour A, Bavarsad N, Fallah M, Khayamian M, Zei F, et al. Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of *L. major* lesion in BALB/c mice. *Exp Parasitol* 2014; 143: 5-10.

[8] Aflatoonian M, Fekri A, Rahnam Z, Khalili M, Pardakhty A, Khazaeli P, et al. The efficacy of combined topical niosomal dapsone gel and intralesional injection of meglumine antimoniate in comparison with intralesional meglumine antimoniate and cryotherapy in the treatment of cutaneous leishmaniasis. *J Pakistan Assoc Dermatol* 2016; 26(4): 353-360.

[9] Farajzadah S, Ahmadi R, Mohammadi S, Pardakhty A, Khalili M, Aflatoonian M. Evaluation of the efficacy of intraleisional Glucantime plus niosomal zinc sulphate in comparison with intraleisional Glucantime plus cryotherapy in the treatment of acute cutaneous leishmaniasis, a randomized clinical trial. *J Parasit Dis* 2018; 42(4): 616-620.

[10] Asadi M, Pardakhty A, Mosafii M, Sharifi I. Preparation and in vivo administration of paromomycin niosomes in balb/c mice. *Res Pharm Sci* 2012; 7(5): e373.

[11] Nesakumar I. Formulation, characterization and evaluation of ketoconazole niosomal gel for the treatment of cutaneous leishmaniasis [Doctoral dissertation]. Chennai: College of Pharmacy Madras Medical College; 2016.

[12] Daie Parizi MH, Karvar M, Sharifi I, Bahrampour A, Heshmat Khah A, Rahnama Z, et al. The topical treatment of anthropometric cutaneous leishmaniasis with the tincture of thioxolone plus benzoctonon chloride (Thio-Ben) along with cryotherapy: A single-blind randomized clinical trial. *Dermatol Ther* 2015; 28(3): 140-146.

[13] Ja EK, Hong SK, Shin YI, Chang SL, Won C, Lee SA, et al. LYR71, a derivative of trimeric resveratrol, inhibits tumorigenesis by blocking STAT3-mediated matrix metalloproteinase 9 expression. *Exp Mol Med* 2008; 40(5): 514-522.

[14] Kim BH, Roh E, Lee HY, Lee IJ, Ahn B, Jung SH, et al. Benzothiole derivative blocks lipopolysaccharide-induced nuclear factor-kappaB activation and nuclear factor-kappaB-regulated gene transcription through inactivating inhibitory kappaB kinase beta. *Mol Pharmacol* 2008; 73(4):1309-1318.

[15] Pardakhty A, Shabibae M, Daneshvar H, Khamesipour A, Mohammadi-Khorsand T, Forootanfar H. Preparation and evaluation of niosomes containing autoclaved *Leishmania major*: A preliminary study. *J Microencapsul* 2012; 29(3): 219-224.

[16] Kumar GP, Rajeshwarao P. Nonionic surfactant vesicular systems for effective drug delivery-an overview. *Acta Pharm Sin B* 2011; 1(4): 208-219.

[17] Chandra D, Naik S. *Leishmania donovani* infection down-regulates TLR2-stimulated IL-12p40 and activates IL-10 in cells of macrophage/monocytic lineage by modulating MAPK pathways through a contact-dependent mechanism. *Clin Exp Immunol* 2008; 154: 224-234.

[18] Bamorovat M, Sharifi I, Mohammadi MA, Eybpoosh S, Nasibi S, Aflatoonian MR, et al. *Leishmania tropica* isolates from non-healed and healed patients in Iran: A molecular typing and phylogenetic analysis. *Microb Pathog* 2018; 116: 124-129.

[19] Bamorovat M, Sharifi I, Aflatoonian MR, Sharifi H, Karamoozian A, Sharifi F, et al. Risk factors for anthropometric cutaneous leishmaniasis in unresponsive and responsive patients in a major focus, southeast of Iran. *PLoS One* 2018; 13(2): e0192236. doi:10.1371/journal.pone.0192236.

[20] Soto J, Soto P, Ajata A, Luque C, Tintaya C, Paz D, et al. Topical 15% paromomycin-aquaphilic for bolivian *Leishmania braziliensis* cutaneous
leishmaniasis: A randomized, placebo-controlled trial. Clin Infect Dis 2019; 68(5): 844-849.

[21]de Morais-Teixeira E, Aguiar MG, Soares de Souza Lima B, Ferreira LAM, Rabello A. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Vianna) braziliensis. J Antimicrob Chemother 2015; 70(12): 3283-3290.

[22]López L, Vélez I, Asela C, Cruz C, Alves F, Robledo S, et al. A phase II study to evaluate the safety and efficacy of topical 3% amphotericin B cream (Anfoleish) for the treatment of uncomplicated cutaneous leishmaniasis in Colombia. PLoS Negl Trop Dis 2018; 12(7): e0006653.

[23]Barrese AA, Genis C, Fisher SZ, Orwenyo JN, Kumara MT, Dutta SK, et al. Inhibition of carbonic anhydrase II by thioxolone: A mechanistic and structural study. Biochemistry 2008; 47(10): 3174-3184.

[24]Tao Y, Li X, Han L, Zhang W, Liu Z. Spectroscopy (FT-IR, FT-Raman), hydrogen bonding, electrostatic potential and HOMO-LUMO analysis of tioxolone based on DFT calculations. J Mol Struct 2016; 1121:188-195.

[25]Innocenti A, Maresca A, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: Thioxolone versus sulfonamides for obtaining isozyme-selective inhibitors? Bioorganic Med Chem Lett 2008; 18(14): 3938-3941.

[26]Hoagland K. Drug repurposing: A study of the potential antitumorogenic activity of nonchemotherapeutic. 2015 USFSP Honor Program Thesis. University of South Florida St. Petersburg; 2015.

[27]Johansen LM, Owens CM, Mawhinney C, Chappell TW, Brown AT, Frank MG, et al. Compositions and methods for treatment of viral diseases. WO2008034666A2 (Patent) 2008.

[28]Moazeni E, Giliani K, Soutodegan F, Pardakhkty A, Najafabadi AR, Ghalandari R, et al. Formulation and in vitro evaluation of ciprofloxacin containing niosomes for pulmonary delivery. J Microencapsul 2010; 27(7): 618-627.

[29]Roy Biswas G, Biswas Majee S. Niosomes in ocular drug delivery. Eur J Pharm Med Res 2017; 4(7): 813-819.

[30]Gupta A, Singh S, Kotla NG, Webster TJ. Formulation and evaluation of a topical niosomal gel containing a combination of benzoyl peroxide and tretinoin for antiacne activity. Int J Nanomed 2015; 10: 171-182.

[31]Basiri L, Rajahzadeh G, Bostan A. Physicochemical properties and release behavior of Span 60/Tween 60 niosomes as vehicle for -tocopherol delivery. LWT 2017; 84: 471-478.

[32]Mahale NB, Thakkar PD, Mali RG, Walunj DR, Chaudhari SR. Niosomes: Novel sustained release nonionic stable vesicular systems- An overview. Adv Colloid Interface Sci 2012; 183–184: 46-54.

[33]Serpa Silva Bosquiroli L, Caroline dos Santos Ferreira A, Souza Farias K, Carneiro da Costa E, de Fátima Cepa Matos M, Cristina Toffoli Kadri M, et al. In vitro anti- leishmaniasia activity of sesquiterpene-rich essential oils from Nectandra species. Pharm Biol 2017; 55(1): 2285-2291.

[34]Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19(1): 111-126.

[35]Duszenko M, Figarella K, Macleod ET, Welburn SC. Death of a trypanosome: a selfish altruism. Trends Parasitol 2006; 22(11): 536-542.

[36]Weingärtner A, Kemmer G, Müller FD, Zampieri RA, Gonzaga dos Santos M, Schiller J, et al. Leishmania promastigotes lack phosphatidylserine but bind annexin V upon permeabilization or miltefosine treatment. PLoS One 2012; 7(8): e42070. doi:10.1371/journal.pone.0042070.

[37]Basmaciyan L, Azas N, Casanova M. Calcine+/PI- as an early apoptotic feature in Leishmania. PLoS One 2017; 12(11): 1-10.

[38]Martorelli D, Muraro E, Merlo A, Turinini R, Fae DA, Rosato A, et al. Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders. Clin Dev Immunol 2012; 3: 931952.

[39]Bogdan BC, Vodovotz Y, Nathan C. Macrophage deactivation by thioxolone: A mechanistic and structural study. Biochemistry 2008; 47(10): 3174-3184.

[40]Amlit A, Fasel N, Coombs GH, Mottram JC. An essential role for the Leishmania major metacaspase in cell cycle progression. Cell Death Differ 2008; 15(1): 113-122.

[41]Raina P, Kaur S. Knockdown of LdMC1 and Hsp70 by antisense oligonucleotides causes cell-cycle defects and programmed cell death in Leishmania donovani. Mol Cell Biochem 2012; 359(1-2): 135-149.

[42]Debrabant A, Lee N, Bertholet S, Duncan R, Nakhusi HL. Programmed cell death in trypanosomatids and other unicellular organisms. Int J Parasitol 2003; 33(3): 257-267.